6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 13 Feb 2024
- Reporting date
- 13 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,805 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 701-725 of 1,000 matching filings.
Per page
25
Current page
29
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 13 Feb 2024
- Reporting date
- 13 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Feb 2024
- Reporting date
- 12 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Feb 2024
- Reporting date
- 12 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Feb 2024
- Reporting date
- 12 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
US FDA FAST TRACK DESIGNATION FOR BEPIROVIRSEN
- Filing date
- 12 Feb 2024
- Reporting date
- 12 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13D/A
AMENDMENT TO SC 13D
- Filing date
- 09 Feb 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13G/A
AMENDMENT TO FORM SC 13G
- Filing date
- 06 Feb 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13G/A
AMENDMENT TO FORM SC 13G
- Filing date
- 06 Feb 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
FDA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK
- Filing date
- 06 Feb 2024
- Reporting date
- 06 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
SHINGRIX 18+ AT RISK CHINA FILING REVIEW ACCEPTED
- Filing date
- 06 Feb 2024
- Reporting date
- 06 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK PRESENTS POSITIVE DREAMM-7 PHASE III DATA
- Filing date
- 06 Feb 2024
- Reporting date
- 06 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 01 Feb 2024
- Reporting date
- 01 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 01 Feb 2024
- Reporting date
- 01 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 01 Feb 2024
- Reporting date
- 01 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
FINAL RESULTS
- Filing date
- 31 Jan 2024
- Reporting date
- 31 Jan 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
File 001-37627
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
- Filing date
- 30 Jan 2024
- Reporting date
- 07 Dec 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
EMA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK
- Filing date
- 29 Jan 2024
- Reporting date
- 29 Jan 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
EUROPEAN COMMISSION AUTHORISES OMJJARA IN THE EU
- Filing date
- 29 Jan 2024
- Reporting date
- 29 Jan 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13D/A
AMENDMENT TO FORM SC 13D
- Filing date
- 19 Jan 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 19 Jan 2024
- Reporting date
- 19 Jan 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 17 Jan 2024
- Reporting date
- 17 Jan 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
CURRENT REPORT
- Filing date
- 17 Jan 2024
- Reporting date
- 16 Jan 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK COMPLETES SALE OF SHARES IN HALEON PLC
- Filing date
- 17 Jan 2024
- Reporting date
- 17 Jan 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 16 Jan 2024
- Reporting date
- 16 Jan 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing